Nfkb1 suppresses DNA alkylation-induced tumor formation

Adam M Schmitt and Bakhtiar Yamini*

Section of Neurosurgery, Department of Surgery, The University of Chicago, Chicago, IL USA

Keywords: DNA damage, lymphoma, NF-κB, tumor suppression, temozolomide

Abbreviations: AML, acute myelogenous leukemia; IR, ionizing radiation; MEF, mouse embryonic fibroblast; MNU, N-methyl-N-nitrosourea; RS, replication stress; t-MN, therapy-related myeloid neoplasia; TMZ, temozolomide.

The NF-κB family is composed of 5 subunit proteins that mediate transcriptional activity as dimers. Whereas p65, c-rel, and reB are translated in their mature form, NF-κB1 (p105) and NF-κB2 (p100) are precursor proteins that are proteolytically processed to form p50 and p52, respectively. Although these subunits can compensate for each other when one is depleted,1,2 each subunit has autonomous actions.3 NF-κB proteins play an important role in carcinogenesis, and both oncogenic and tumor suppressive actions have been described.4 However, targeted deletion of each protein has not revealed a direct tumor suppressive role for any subunit.3

DNA damage induced either by endogenous/environmental sources or by chemotherapeutic agents is an important cause of carcinogenesis. Although damage repair is the primary mechanism for maintenance of genomic integrity in the setting of DNA damage, cytotoxic pathways also play an important role in eliminating damaged cells. Propagation of DNA damage results in mutations that can eventually lead to tumor formation. A particularly devastating example of this is therapy-related myeloid neoplasia (t-MN).5 This heterogeneous disease occurs after treatment of an initial cancer with cytotoxic agents and has become a significant clinical problem as cancer survivorship has improved. More than 75% of patients that develop t-MN have received an alkylating agent for the management of their primary tumor.6

In examining the role of NF-κB signaling in the response to DNA damage, we previously reported that the p50/NF-κB1 subunit is necessary for cytotoxicity induced by alkylating agents such as temozolomide (TMZ) and N-methyl-N-nitrosourea (MNU), but not that induced by ionizing radiation (IR).7 Loss of p50/NF-κB1 modulates cytotoxicity by rendering cells tolerant of the induced damage without affecting damage repair. Thus, cells with reduced p50 continue to survive despite having elevated levels of damage (Fig. 1A). Given that damage accumulation is mutagenic, it was hypothesized that NF-κB1 acts to maintain genomic stability in the setting of DNA alkylation damage.

To study this hypothesis, we first examined the induction of mutation following treatment with a DNA damaging agent.7 Loss of Nfkb1 in mouse embryonic fibroblasts (MEFs) led to increased generation of mutations in response to TMZ but not IR, suggesting that Nfkb1 acts to maintain genome stability. Subsequently, to examine whether this subunit actually mediates tumor suppression we examined whether deletion of Nfkb1 modulates alkylator-induced tumor formation using an animal carcinogenesis model. Remarkably, at 1 y, significantly more thymic lymphomas were induced by MNU in Nfkb1−/− than Nfkb1+/+ animals (P < 0.0001). Moreover, this differential tumor formation was evident at multiple MNU concentrations regardless of whether the animals were on a mixed (B6/129) or pure (C57BL/6) background. Interestingly, consistent with the lack of effect of Nfkb1 loss on IR-induced mutation induction or cytotoxicity,2 no significant difference in tumor formation rate was noted between Nfkb1−/− and Nfkb1+/+ animals following whole-body IR. Together, these findings indicated that Nfkb1 protects mice against alkylation-induced, but not IR-induced, tumor formation and suggested that this subunit acts as a pathway-specific tumor suppressor.

Heterozygous animals were noted to have a tumor induction rate intermediate...
between that of Nfkb1\(^{-/-}\) and Nfkb1\(^{+/+}\) mice (Fig. 1B). Examination of tumor tissue from animals of all 3 genotypes demonstrated that p105 and p50 were present at both the gene and protein level in the tumors from Nfkb1\(^{+/+}\) animals. In addition, the ability of p50 from these tumors to dimerize and bind DNA was confirmed using gel shift analysis. These findings indicated that tumors from heterozygous mice retain functional p50, supporting the hypothesis that Nfkb1 mediates tumor suppression in a haploinsufficient manner.

Having examined NF-kB1 in mice, we were interested in whether this subunit mediates tumor suppression in humans. Therefore, we examined NFKB1 mRNA expression in a series of published databases of human hematological malignancies. Almost invariably, it was apparent that tumor tissue has substantially lower NFKB1 expression compared to that in patients with de novo AML, which occurs without a history of prior alkylator treatment. The mRNA expression was reflected by similar changes at the protein level.

In summary, our work demonstrates that NF-kB1 is a tumor suppressor that maintains genome stability in response to DNA damage. Moreover, the human malignancy data support the contention that this subunit mediates tumor suppression in humans. It is evident that this tumor suppressive effect is damage-type specific from the observation that Nfkb1 does not prevent tumor formation in response to IR or other carcinogens. In fact, we recently noted that p50/NF-kB1 mediates the cytotoxic response specifically to any agent, or process, that induces replication stress (unpublished data, BY). Our work shows that Nfkb1 acts in a haploinsufficient manner, suggesting that reduced expression is sufficient to attenuate tumor suppression. This observation is relevant to humans because, although NFKB1 is rarely deleted or mutated in human tumors, reduced expression is common. Low NFKB1 expression may be a normal variant found in the population, or may be a secondary response to the expression of an oncogene such as myc, tal1, bcl-6, or lmo1 (for citations see ref. 7). From a mechanistic standpoint, a decrease in p50 results in compensation by p52. However, although p52 can cross-compensate for p50 in certain respects it cannot functionally compensate for p50 in the cytotoxic response to DNA alkylation.

We propose that this deficiency in the damage response results in survival of injured cells, ultimately leading to genome instability. Given the lack of increased basal tumor formation with loss of Nfkb1,\(^{-/-}\) we propose that this subunit is a low penetrance cancer susceptibility gene that acts in combination with other factors to determine the overall response to genomic insults.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Figure 1.** Nfkb1 maintains genome stability in response to DNA alkylation damage. (A) p50 (NF-kB1) mediates cytotoxicity in response to DNA damage. Loss of this subunit results in survival of cells with elevated levels of damage, leading to increased mutagenesis. (B). Alkylator-induced tumor formation is suppressed by Nfkb1 in a haploinsufficient manner.
References

1. Hoffmann A, Leung TH, Baltimore D. Genetic analysis of NF-kappaB/Rel transcription factors defines functional specificities. Embo J 2003; 22:5530-9; PMID:14532125; http://dx.doi.org/10.1093/emboj/cdg534

2. Schmitt AM, Crawley CD, Kang S, Raleigh DR, Yu X, Wahlstrom JS, Voce DJ, Darga TE, Weichelbaum RR, Yamini B. p50 (NF-kappaB1) is an effector protein in the cytotoxic response to DNA methylation damage. Mol Cell 2011; 44:785-96; PMID:22152481; http://dx.doi.org/10.1016/j.molcel.2011.09.026

3. Gerondakis S, Grumont R, Gugasyan R, Wong L, Isoyama I, Ho W, Banerjee A. Unravelling the complexities of the NF-kappaB signalling pathway using mouse knockout and transgenic models. Oncogene 2006; 25:6781-99; PMID:17072328; http://dx.doi.org/10.1038/sj.onc.1209944

4. Perkins ND. NF-kappaB: tumor promoter or suppressor? Trends Cell Biol 2004; 14:64-9; PMID:15102437; http://dx.doi.org/10.1016/j.tcb.2003.12.004

5. Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 2005; 5:943-55; PMID:16294218; http://dx.doi.org/10.1038/nrc1749

6. Smith SM, Le Beau MM, Hsu D, Karrison T, Sobecks RR, Anastasi J, Vardiman JW, Rowley JD, Larson RA. Clinical-epigenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003; 102:43-52; PMID:12623843; http://dx.doi.org/10.1182/blood-2002-11-3343

7. Voce DJ, Schmitt AM, Uppal A, McNerney ME, Bernal GM, Cahill KE, Wahlstrom JS, Nasiri A, Yu X, Crawley CD, et al. Nfkb1 is a haploinsufficient DNA damage-specific tumor suppressor. Oncogene 2014; PMID:25043302

8. Glaeurt HP, Eyigor A, Tharappel JC, Cooper S, Lee EF, Spear BT. Inhibition of hepatocarcinogenesis by the deletion of the p50 subunit of NF-kappaB in mice administered the peroxisome proliferator Wy-14,643. Toxicol Sci 2006; 90:331-6; PMID:16434500; http://dx.doi.org/10.1093/toxsci/kfj116

9. Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JF, Bailey-Wilson JE, Silverberg MS, Duerr RH, Cho JH, Gregersen PK, et al. Functional annotation of a novel NFkB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004; 13:35-45; PMID:14613970; http://dx.doi.org/10.1093/hmg/ddh008

10. Sha WC, Liu HC, Tuomanen EI, Baltimore D. Targeted disruption of the p50 subunit of NF-kappaB leads to multifocal defects in immune responses. Cell 1995; 80:321-30; PMID:7834752; http://dx.doi.org/10.1016/0092-8674(95)90415-8